This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Glaukos Stocks Rides on Strong Product Demand Amid Competition
by Zacks Equity Research
GKOS continues to benefit from a robust product portfolio and a strong pipeline. However, stiff competition remains a woe.
MASI Stock Down Despite New SafetyNet Deal for Neonatal Care
by Zacks Equity Research
The latest adoption of Masimo's SafetyNet is likely to improve the care provided to premature newborns and facilitate their early discharge from the hospital.
iRhythm Stock Gains Following Favorable Zio Monitor Study Data
by Zacks Equity Research
IRTC announces initial findings demonstrating the superior real-world performance of the next-generation Zio LTCM Monitor at the HRX 2024 meeting.
Femasys Stock Rises After FDA Clearance for FemChec Diagnostic Device
by Zacks Equity Research
FEMY gains after FDA clearance for FemChec, a fallopian tube diagnostic tool designed for safe, in-office use, enhancing non-surgical birth control procedures.
Here's Why You Should Retain PDCO Stock in Your Portfolio for Now
by Zacks Equity Research
Investors remain optimistic about Patterson Companies on the back of its broad product line.
Here's Why You Should Retain Glaukos Stock in Your Portfolio Now
by Zacks Equity Research
GKOS continues to benefit from a robust demand for its products as well as expansion in new markets. A strong development pipeline raises optimism.
PBH Stock Might Get a Boost From Focused Brand-Building Efforts
by Zacks Equity Research
Prestige Consumer puts emphasis on brand building and product innovation in niche consumer healthcare categories to improve the lives of its consumers.
Fresenius Medical Care Stock Rises on NxStage VersiHD Launch
by Zacks Equity Research
FMS introduces NxStage VersiHD with GuideMe Software to simplify home dialysis and grow its patient base in the United States.
VEEV Stock Up Following the Release of New Features of Veeva Site Connect
by Zacks Equity Research
Veeva Systems' Site Connect is likely to aid the sponsors in reducing trial time and expense.
iRhythm Stock May Gain on Its Latest Deal With BioIntelliSense
by Zacks Equity Research
IRTC announces an exclusive license agreement with BioIntelliSense to develop and commercialize certain patented technology assets within AMC.
COO Stock Up 0.4% Following the Launch of New Inserter for Paragard IUD
by Zacks Equity Research
Cooper Companies' latest launch is likely to simplify the insertion process of Paragard IUD, thus making it a more accessible contraceptive choice.
DENTSPLY SIRONA Stock May Gain on the Launch of Primescan 2
by Zacks Equity Research
XRAY introduces its new-generation intraoral scanner, Primescan 2, to provide effective and efficient care and comfort to patients.
McKesson Shares Fall Following Sale of Rexall, Well.ca to Birch Hill
by Zacks Equity Research
MCK announces the sale of its Canada-based Rexall and Well.ca businesses to Birch Hill Equity Partners, aligning with its strategy to grow oncology and biopharma services.
HealthEquity Stock May Gain From Its Latest Partnership With Paytient
by Zacks Equity Research
HQY collaborates with Paytient to enhance employees' access to healthcare through Health Payment Accounts.
Intuitive Surgical Gains 40.5% Year to Date: What's Driving the Stock?
by Zacks Equity Research
ISRG's shares gain on the back of strength in da Vinci surgical system.
BD Stock Falls After Acquisition of Edwards' Critical Care Group
by Zacks Equity Research
BDX expands its smart care portfolio by acquiring Edwards Lifesciences' Critical Care group, now BD Advanced Patient Monitoring, strengthening AI-driven health solutions.
Why Quest Diagnostics (DGX) is a Top Value Stock for the Long-Term
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
HealthEquity Stock Rises on Q2 Earnings and Revenue Beat
by Zacks Equity Research
HQY surpasses second-quarter expectations on robust HSA growth and improved margins. It also raises FY25 guidance.
Elevance Health Stock Has More to Offer: Should You Hold on Tight?
by Zacks Equity Research
In the commercial category, an increase in individual as well as employer group fee-based memberships will continue supporting ELV's medical membership numbers.
AngioDynamics Stock Falls Despite CE Mark for Auryon System
by Zacks Equity Research
ANGO's Auryon Atherectomy System earns CE Mark, which expands its European market reach and enhances PAD treatment with advanced laser technology.
Ensign Adds 8 Facilities in Kansas & Colorado to Expand Footprint
by Zacks Equity Research
The acquisition deals increase ENSG's portfolio to encompass 323 healthcare operations spanning 14 states.
Greenville Center to Boost CAH Stock's at-Home Solution Business
by Zacks Equity Research
Cardinal Health announces the opening of its new distribution center in Greenville to support its at-Home Solutions business.
Femasys Shares Rise on CE Mark & Canada Approval for FemVue MINI
by Zacks Equity Research
FEMY's eco-friendly FemVue MINI receives CE Mark and Health Canada approval, advancing sustainable fallopian tube assessment technology in Europe and Canada.
Encompass Health Stock Rises 39.4% YTD: Should You Buy Now?
by Zacks Equity Research
To meet the increasing demand for its services, EHC is expected to continue adding beds.
Delcath Systems Stock Gains on Positive CHEMOSAT Melanoma Data
by Zacks Equity Research
DCTH's study of the CHEMOSAT Hepatic Delivery System shows that the device significantly boosts survival rates in uveal melanoma patients with liver metastases, outperforming systemic therapies.